Drug Discovery Stories, Volume 2 - Softcover

Softcover

ISBN 10: 044333885X ISBN 13: 9780443338854

Publisher: Elsevier, 2025

Synopsis

Drug Discovery Stories, Volume Two showcases the discovery journeys of recent blockbuster drugs approved between 2023 and 2024, along with promising drug candidates. This book delves into structural biology, biological functions of targets, hit compound identification, hit-to-lead optimization, binding modes, key biological and pharmacokinetic data, and clinical results. It also covers other candidate compounds against the same targets and includes additional content based on the authors' choices. The series addresses the rapid evolution in drug discovery and development, appealing to those in chemical biology, synthetic chemistry, and pharmacology.

By highlighting interdisciplinary collaboration, the authors plan to release updated editions every few years to ensure the content reflects the latest achievements and breakthroughs in the field.

• Analyzes the drug discovery stories of different blockbuster drugs
• Covers key aspects related to the drug development of the drugs
• Includes the newly approved drugs

About this title

About the Authors

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010-2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.

From the Back Cover

The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology. By showcasing how their work is utilized or has the potential to be utilized in the realm of drug discovery, this series intends to foster interdisciplinary collaboration and knowledge exchange. Considering the dynamic nature of drug discovery and development, where progress is swift and continuous, the authors have planned to release updated editions of the book every few years, ensuring that the content remains up to date with the latest achievements and breakthroughs in the field. Drug Discovery Stories, Volume 2 presents drug discovery stories of blockbuster drugs recently approved (2023-2024) and other promising drug candidates, including the structural biology and biological functions of the targets of interest, the identification of hit compounds, hit-to-lead optimization, binding mode of the key compounds with the target of interest (practically those guiding the drug design), key biological and PK data of lead compounds, clinical results if any, other candidate compounds in preclinical and clinical stage against the same target, and other contents that the authors want to include based on their choices.

Edition details

• Publisher: Elsevier
• Publication date: 2025
• Language: English
• ISBN 10: 044333885X
• ISBN 13: 9780443338854
• Binding: Paperback
• Number of pages: 758
• Editor: Yu PhD Bin, Zhan Peng